All In Biotech

Drug Trial Radar · NCT03140969

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

An Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

11

Actual

Start

Oct 16, 2017

Primary completion

Oct 2, 2019

Study completion Oct 2, 2019

Sponsor

Lead sponsor
Laboratoires TheaIndustry
Sponsor type
Industry
Collaborators
Sepul Bio
First posted
May 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.

Conditions

  • Leber's Congenital Amaurosis

Interventions

  • QR-110Drug

    RNA antisense oligonucleotide for intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral EyesTime frame: 1 year

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Iowa

    Iowa City, Iowa

  • Scheie Eye Institute, University of Pennsylvania

    Philadelphia, Pennsylvania

  • Ghent University Hospital and Ghent University

    Ghent, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.